Renal effects of antihypertensive therapy in uninephrectomized diabetic rats

Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie
B GallegoF Pérez-Barriocanal

Abstract

Diabetic nephropathy is a major cause of chronic renal failure. The evidence available indicates that renal hemodynamics are altered in clinical and experimental diabetes mellitus. In these circumstances, an increased glomerular filtration rate (GFR) is associated with albuminuria and eventually with glomerulosclerosis. We studied the renal and hemodynamic effects of long-term treatment (5 months) using an angiotensin-converting enzyme inhibitor (trandolapril, 0.7 mg/g b.w. per day) and a calcium antagonist (verapamil, 20 mg/g b.w. per day), and the combination of the two (veratran) at the same dose, on streptozotocin-diabetic uninephrectomized rats. A moderate degree of hyperglycemia (2-4 g/l) was maintained with daily insulin. Mean arterial pressure (MAP) was measured monthly using the tail-cuff method. Determinations were made of urinary protein excretion, creatinine clearance, urinary electrolyte excretion and, at the end of treatment, renal and cardiac hypertrophy. MAP was similar in control and untreated diabetic rats. Trandolapril and veratran reduced MAP whereas verapamil alone had no effect on these animals. All groups showed a slight proteinuria that increased with verapamil treatment. The GFR of diabetic animals was ...Continue Reading

References

Apr 1, 1992·The American Journal of Physiology·M J DavisJ D Hood
Apr 1, 1992·Kidney International·S AndersonB M Brenner
Dec 1, 1991·The Journal of Physiology·A López-FarréJ M López-Novoa
Dec 1, 1989·Kidney International·F P BrunnerM J Mihatsch
Jan 1, 1987·Contributions to Nephrology·E RitzJ F Mann
Oct 5, 1988·The American Journal of Cardiology·J P TolinsL Raij
Mar 1, 1988·Diabetes/metabolism Reviews·K S Kleinman, L G Fine
Feb 1, 1987·Kidney International·C E Mogensen
Jan 1, 1987·Kidney International·D C HarrisR W Schrier
Apr 1, 1986·Clinical and Experimental Pharmacology & Physiology·B JacksonC I Johnston
Sep 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·R ZatzB M Brenner
Sep 27, 1985·The American Journal of Medicine·L Raij, W F Keane
Mar 1, 1981·Kidney International·T H HostetterB M Brenner
Jan 1, 1994·Journal of Cardiovascular Pharmacology·D Hoelscher, G Bakris
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert

❮ Previous
Next ❯

Citations

Sep 12, 2000·Current Hypertension Reports·A A Taylor, S Sunthornyothin
May 16, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·B Nielsen, A Flyvbjerg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.